Category: Latest News
-
Neuronetics Narrows Q2 Loss as Greenbrook Growth Drives 9% Revenue Increase
Neuronetics improved margins, reached positive adjusted EBITDA and lowered its 2026 operating expense outlook, although NeuroStar revenue declined during the quarter. Key Investor Takeaways Why STIM Stock Is in Focus Neuronetics’ Q2 loss narrowed substantially as growth at its Greenbrook clinics, margin expansion and lower expenses moved the company closer to profitability. Total revenue increased…
-
Mereo BioPharma Extends Cash Runway Into Late 2027 as Alvelestat Phase 3 Partnership Advances
The rare-disease biotech cut its quarterly net loss while a new Sentynl agreement could provide $40 million in upfront and R&D payments and funding for alvelestat’s planned Phase 3 study. Key Investor Takeaways Why MREO Stock Is in Focus Mereo BioPharma’s updated cash runway into late 2027 gives the clinical-stage company additional operating visibility while…
-
Senmiao Technology Targets 100 MW Initial Digital Infrastructure Development Through Energence Utah Partnership
The proposed $5 million staged investment would give Senmiao an initial position in a Utah infrastructure campus targeting 100 MW of firm capacity by Year 2 and potentially up to 1.2 GW by Year 6. Key Investor Takeaways Why AIHS Stock Is in Focus Senmiao Technology’s proposed Energence Utah partnership represents an early move in…
-
Legend Biotech shares rise 5% as Q2 earnings and revenue beat estimates
Legend Biotech Corporation (NASDAQ:LEGN) shares gained 5.5% in pre-market trading on Tuesday after the pharmaceutical company delivered better-than-expected second-quarter earnings and revenue, supported by continued growth in CARVYKTI sales. Adjusted earnings came in at $0.16 per share, more than double the analyst consensus of $0.07. Revenue reached $387.5 million, ahead of the $362.81 million estimate…
-
Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum
Autolus Therapeutics plc (NASDAQ:AUTL) shares rose 3.19% in pre-market trading on Tuesday after the biotechnology company delivered better-than-expected second-quarter results and raised its full-year revenue guidance for AUCATZYL. Autolus reported a loss of $0.15 per share, narrower than the consensus forecast for a $0.23 loss. Revenue reached $45.7 million, comfortably exceeding the $30.1 million analyst…
-
ACV Auctions stock jumps 12% on report of potential sale exploration
ACV Auctions (NASDAQ:ACVA) shares jumped 12% on Tuesday following a report that the digital automotive marketplace is exploring strategic alternatives, including a potential sale, after attracting takeover interest. Bloomberg reported that the Buffalo, New York-based company is working with financial advisers on the review. ACV is also considering a strategic partnership as another possible option.…
-
Broadwind stock falls 6% as Q2 revenue misses estimates despite strong growth
Broadwind Energy Inc. (NASDAQ:BWEN) shares fell 5.83% in pre-market trading on Tuesday after the precision manufacturer reported second-quarter revenue and earnings below analyst expectations, despite substantial year-on-year growth following its exit from wind tower manufacturing. Broadwind reported a loss from continuing operations of $0.03 per share, compared with the consensus estimate for a $0.01 loss.…
-
Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares jumped 7.88% in pre-market trading on Tuesday after the specialty pharmaceutical company reported second-quarter earnings and revenue above analyst expectations, supported by continued growth in PEDMARK sales. Adjusted earnings came in at $0.05 per share, exceeding the analyst consensus of $0.02 by $0.03. Revenue reached $17.87 million, ahead of the…
-
First Advantage shares fall 8% after Silver Lake secondary share offering
First Advantage (NASDAQ:FA) shares fell 8% on Tuesday morning after investment funds affiliated with Silver Lake Group announced plans to sell 12.5 million shares of the background screening and identity solutions company through a secondary offering. According to Bloomberg, the shares are being marketed at between $22.20 and $23.59 each. First Advantage shares closed Monday…
-
Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances
Bicara Therapeutics Inc. (NASDAQ:BCAX) shares gained 3.32% in pre-market trading on Tuesday after the clinical-stage biopharmaceutical company reported continued enrollment progress in its pivotal FORTIFI-HN01 study and maintained its timeline for an interim analysis in 2027. The company reported a second-quarter loss of $0.82 per share for the period ended June 30, 2026. Net loss…